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Background: The aim of the present study was to measure the clinical and pain score in these patients and to measure the
level of IL-17 in saliva of patients having different forms of Oral lichen planus lesions (OLP).
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1.

Subjects and methods: According to sample size calculation, the present study was done on a total of 40 subjects divided into
3 groups Group (I) Twenty patients having erosive/atrophic OLP. Group (II) Ten patients having reticular OLP and Group
(III) Ten healthy control patients. Salivary samples were collected from the subjects of the three groups to evaluate the levels
of IL-17 using enzyme-linked immunosorbent assay (ELISA).
Results: The values of the clinical and pain score were statistically significantly higher in the erosive/atrophic group than both
the reticular and healthy control subjects. The levels of IL-17 in saliva of patients with erosive/atrophic OLP were statistically
significantly higher than in patients with the reticular OLP and healthy control subjects, and there was a high statistically
significant difference between the reticular group and the healthy control subjects p<0.001.
Conclusions: According to the results, the salivary levels of IL-17 are higher in the erosive/ atrophic type of OLP than the
reticular type and both are higher than the healthy control subjects. This suggested that IL- 17 has a great role in the immunepathogenesis of OLP and may be of diagnostic value for the severity of the condition of the erosive/atrophic OLP.

INTRODUCTION

Oral lichen planus is an immune mediated chronic disease which affects
the oral mucous membranes. It tracks acyclic pattern of exacerbations or
flares followed by periods of remission, contrasting lichen planus of the skin,
which has been reported to have a high rate of spontaneous remission. (1) It
usually presents asymmetrical and bilateral lesions, where it may also present
as multiple lesions in the mouth. The clinical presentation of the oral lesions
is present in six forms: papular, reticular and plaque-like lesions, atrophic,
erosive/ ulcerative and bullous lesions. The papular, reticular and plaque- like
lesions are asymptomatic while the atrophic, erosive/ ulcerative and bullous
lesions are esymptomatic with symptoms ranging from soreness to severe

to efficiently induce the lineage- specific transcription factor retinoic-acidreceptor- related orphan nuclear receptor γt (RORγt) a key regulator of Th17
differentiation as well as IL-17 production. T helper 17 cells are critically
involved in host defense, inflammation and autoimmunity (4).
The role of interleukin-17 (IL-17) in the immune- pathogenesis of
OLP has been emerged. A huge development in this field occurred with the
acknowledgment that IL-17- producing CD4+ T cells are developed as a
population distinct from the classic T helper type 1 (Th1) and T helper type
II (Th2) cells (5,6).

The reason of OLP is not completely known. Many etiological factors
have been suggested for the etiology like genetic predisposition, bacterial and
viral infections, autoim- mune diseases, immunodeficiency, stress, trauma and
systemic diseases such as diabetes, hypertension, malignant neoplasms and
bowel disease (3).

Interleukin-17 (IL-17) is one of the cytokines produced by Th17.
Interleukin-17 and other Th17 cytokines are related to the pathogenesis of
diverse autoimmune and inflammatory diseases. It is also important for host
defense against many microbes, particularly extracellular bacteria and fungi.
IL-17 induces chemokine release from various cell types of the skin, including
endothelial cells, macrophages, and keratinocytes leading to tissue remodeling
and the recruitment of pro- inflammatory effector cells of the oral mucosa
which denotes its critical role in the pathogenesis of OLP (7).

T helper 17 (Th17) cells were recognized as a new subclass of CD4+
T helper cells in 2005. The Th17 differentiation requires both inflammatory
cytokines which are: IL-6, IL- 21 and transforming growth factor β (TGF- β)

In 2014, Shen et al., conducted a study on 42 patients having OLP and
38 patients having skin LP and 10 normal control patients having no lesions
and found that IL-17 levels expression in the oral tissues of patients with LP

burning pain

(2)

.
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and OLP was significantly higher compared to the healthy patients who had
no lesions (8). Another study by Kun et al., on 45 patients, 15 were having
erosive/atrophic OLP patients, 15 were having reticular OLP patients and 15
healthy volunteers, and they studied the levels of salivary IL-17 in the three
groups. They found a statistically significant difference between the erosive/
atrophic group and the reticular group and between the erosive/atrophic group
and the healthy control group (9).
2.

AIM OF THE STUDY

To measure the clinical and pain score in these patients and to measure
the level of IL-17 in saliva of patients having different forms of Oral lichen
planus lesions (OLP).
3.

SUBJECTS AND METHODS

In this study forty patients were selected; twenty of them were having
erosive-atrophic OLP, ten were having reticular OLP and ten healthy volunteers.
These patients were evaluated for their eligibility for this study. All subjects
were chosen from the out- patient clinic of Oral Medicine, Periodontology,
Oral Diagnosis and Radiology department Faculty of Dentistry Ain Shams
University and Oral Medicine, periodontology and oral Diagnosis department
Faculty of Dentistry Future University.
4.

STATISTICAL ANALYSIS

Categorical data were presented as frequencies and percentages and were
analyzed using chi square test. Numerical data were tested for normality using
Shapiro Wilk test and were presented as mean and standard deviation values.
Para- metric data were analyzed using one-way ANOVA followed by Tukey‘s
post hoc test for intergroup comparisons. Non- parametric data were analyzed
using Kruskal wallis test followed by pairwise comparisons utilizing Mann
Whitney U test with Bonferroni correction for intergroup comparisons. The
significance level was set at p 0.05 within all tests. Statistical analysis was
performed with IBM3® SPSS® Statistics Version 26 for Windows.

The forty subjects were divided into three groups in which:
Group I consisted of twenty patients with atrophic/erosive OLP. Group II
consisted of ten patients with reticular OLP. Group III consisted of ten healthy
control volunteers with no OLP or any other oral or skin lesion.
Sampling: The un-stimulated whole saliva (UWS) was collected between
9:00 a.m. and 11:00 a.m., and 90 minutes after the last drinking any drinks or
eating any food. It is collected by asking the patients to swallow then tilt their
head forward, and the salivary sample was taken by aspiration using sterile
sterile syringe and stored in Eppendorf tubes at once, and put to freeze at
or under -20ºC to avoid the growth of any bacteria and preserve the saliva
samples from degradation. IL-17 levels were measured using Human IL17 (ELISA) kits delivered from BMS2017/BMS2017TEN supplied from
eBioscience, Affymetrix (Vienna, Austria).
The clinical and pain score values were measured and the samples of
saliva were taken from patients of the three study groups Clinical scoring (CS)
was measured in which the marker lesion in each patient was assessed for
areas of reticulation, erosion, and ulceration by visual examination and the
scoring was recorded as following:
0: Represented no lesion/normal mucosa.
1: Mild white striae/no erythematous area.
2: White striae with atrophic area less than 1 cm2
3: White striae with atrophic area more than 1cm2 4: White striae with erosive
area less than 1 cm2
5: White striae with erosive area more than 1 cm2 (11).
Pain visual Analog Scale (P-VAS) was measured in which the pain VAS
consisted of a 10-cm horizontal line marked 0–10 (0 no pain; 10 most severe
pain experienced). Patients marked the scale at each visit, and the all P-VAS
were included on one sheet of paper allowing the patient to think in terms of
change instead of absolutes. The P-VAS was then scored by measuring from
the patient‘s mark to the beginning of the scale in cm (12).
5.

CASE PRESENTATION

At the first visit before the initiation of the study information including:
age, gender, disease process, medical history, drug history, family history, and
clinical signs and symptoms were documented for each patient.
Patients having OLP were examined clinically by magnifying mirror
using spot light for the oral lesions, the distribution of the lesions and the
affected areas were recorded, also their skin was examined and there were no
extra-oral manifestations. A punch biopsy was taken to confirm the diagnosis
of OLP by histological examination.
Inclusion criteria:
Subjects of both genders were selected, their age from 30 to 60 years
and didn’t suffer from any systemic, infectious and allergic diseases. They
were also selected having no oral lesions except OLP, and had no history of
any treatments which can affect OLP from less than two weeks for topical
medications and four weeks for systemic medications prior to starting the
study (10).

Figure A — A photograph showing atrophic erosive form of oral
lichen planus occupying nearly the whole right and left buccal mucosa
presented as a large shallow atrophy surrounded by wickham‘s striae
radiating from their periphery in a female patient of 52 years old.

Exclusion criteria:
Pregnant/breast-feeding mothers, vulnerable group of patients (prisoners,
handicapped and mentally retarded patients.
Ethical procedures:
All subjects were provided with full verbal and written in- formation
on the protocol of this study and a written informed consent was taken from
each subject. The study was approved by the ethical committee of faculty of
dentistry Ain Shams University and took the number FDAsuRecIM021824.
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Figure B — A photograph showing reticular form of oral lichen planus
presented as a white keratotic lesion with fine lines “wickham‘s striae”
on the right and left buccal mucosa in a female patient of 45 years old.
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RESULTS

Table (1) & figure (1) showing Mean and (SD) values for (CS) in the three
groups. (Group I: erosive/atrophic group, Group II: the reticular group
and Group III: the healthy control subjects)
(CS) (Mean±SD)
Follow up

p-value
Group I

Group II

Group III

4.37±0.69A

1.00±0.00B

0.00±0.00B

<0.001*
7.

DISCUSSION

In this study, the clinical and pain visual analogue scores was evaluated
and there was a highly statistically significant difference for the clinical score
between the erosive/atrophic group and both the reticular and control groups
(p<0.001). These results were in accordance with the results of Chainani et al.,
where they found that there was a statistically significant difference between
the erosive patients of OLP and the reticular patients of OLP (p<0.001) (13).

There was a highly statistically significant difference (p<0.001) in the
mean and SD values of the CS between group one and each of group II and III
where the mean and SD value in group I was (4.37±0.69) and in group II it
was (1.00±0.00) and group III it was (0.00±0.00).
Also there was a highly statistically significant difference (p<0.001) in the
mean and SD values of (P- VAS) between group I and each of group II and
III where the mean and SD values in group I was (7.27±0.92) and for group
II and III it was (0.00±0.00).
Table (2) showing Mean and (SD) values for (P-VAS) in the three
groups. (Group I: erosive/atrophic group, Group II: the reticular group
and Group III: the healthy control subjects)
(CS) (Mean±SD)
Follow up

Baseline

Group I

Group II

Group III

7.27±0.92A

0.00±0.00B

0.00±0.00B

p-value

<0.001*

Concerning the IL-17 levels in saliva, there was a highly statistically
significant difference between the mean and SD values of salivary IL-17
levels between group (I) and each of group (II) and group (III) and between
group (II) and group (III) (p<0.001). Where the mean and SD values of IL17
levels in saliva in group (I) was (50.66±2.30 pg./ml) and for group (II) it was
(39.23±1.57 pg/ml) while for group (III) it was (33.52±0.84pg/ml).
Table (3) and figure (2) showing the mean and (SD) values for IL-17
salivary concentration between the three groups.
(CS) (Mean±SD)
Follow
up

Group I

Group II

Group III

Baseline

50.65±2.29A

39.24±1.56B

33.51±0.83C

Published by Arab Journals Platform, 2021

p- value
<0.001*

Also the results of the present study regarding the clinical score were in
accordance with another study by Siponen et al., they measured the clinical
score and they found that there was a statistically significant difference
between the erosive/atrophic OLP group and reticular group (14).
The results of the present study regarding the (P- VAS) were in accordance
with Suzan and Hadir, where they found that there was an highly statistically
significant difference between the erosive/atrophic group and reticular group
(p<0.001) (15).
Regarding the levels of IL-17 in saliva there was a highly statistically
significant difference in the values of IL-17 salivary levels between the
erosive/atrophic group and both the reticular and control groups, and there
was a statistically significant difference in the values of IL-17 salivary
levels between the reticular group and control group. These results were in
accordance with the results of the study conducted by Kun et al as they found
a statistically significant difference between the erosive/atrophic group and
both the reticular and the healthy control group, but they found that there was
no statistical significant difference between the reticular group and the healthy
control group (9).
Another study by El-Refai et al., as they measured the concentration of
IL-17 in patients having OLP compared to healthy control groups, They found
that there was a high statistically significant difference in the concentration of
IL-17 in saliva in the OLP than in the healthy control individuals (16).
8.

CONCLUSION

This study verified that the clinical score values in patients with erosive/
atrophic form of OLP are higher compared to patients with either reticular
form or healthy controls. Also the concentration of IL-17 in saliva in patients
with erosive/atrophic form of OLP are higher than in patients with the reticular
form and both are higher than the healthy control subjects. According to these
results, we concluded that IL-17 has a great role in the immune-pathogenesis
of OLP and could be used as a salivary diagnostic marker for OLP conditions.
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